世界の急性骨髄性白血病（AML）治療市場：予測と動向

Report Overview

The global acute myeloid leukemia (AML) treatments market should reach $6.1 billion by 2028 from $3.8 billion in 2023 at a compound annual growth rate (CAGR) of 10.0% for the forecast period of 2023 to 2028.

Summary:

The global AML treatment market was valued at nearly $REDACTED billion in 2022. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED%, expected to reach $REDACTED billion by 2028. Growth in this market is fueled by a worldwide increase in elder populations and an increased prevalence of AML.

Technological innovation is an important catalyst driving the adaptation and use.

In 2020, AML treatment was significantly impacted by the COVID-19 pandemic, which led to the shutdown of cancer hospitals and chemotherapy procedures. The transition towards normalcy in the second half of 2021 and the resumption of elective procedures is driving sales of AML treatments.

In 2022, the targeted therapy segment held the highest market share at about REDACTED%, followed by anthracycline drugs at REDACTED% and other chemotherapies at REDACTED%

Reasons for Doing This Study:

The prevalence of Acute Myeloid Leukemia (AML) is rising among the elder population, coinciding with an overall increase in the elder population. This can be attributed to lower mortality rates and a decrease in fertility rates. Advancements in technology within the field of blood cancer are instrumental in driving growth in the AML treatment market.

The COVID-19 pandemic had significant impact on the treatment rates for AML. Lockdown measures and restricted patient access to chemotherapy treatments resulted in a decline in treatment rates during this period.

The primary objective of this study is to provide a thorough analysis of the AML treatment market, facilitating a better understanding of its dynamics, trends and the overall landscape of the market.

Report Synopsis

Report Scope:

This report aims to comprehensively study the market size of AML and treatments for a global market. Current and historical market revenues can be estimated based on treatment type, route of administration, end use, distribution channel and region.

Report Includes:

• 42 data tables and 57 additional tables
• An overview of the global market for acute myeloid leukemia (AML) treatment
• Analyses of global market trends, with data from 2020 to 2022, estimates for 2023 and projections of compound annual growth rates (CAGRs) through 2028
• Highlights of the market potential and characterization of AML market based on treatment type, route of administration type, end-users, distribution channel, region
• Coverage of various risk factors associated with AML, such as exposure to radiation or chemicals, genetic disorders, and weakened immune system
• Description of major treatment options for AML such as, chemotherapy, targeted therapy, and stem cell transplantation
• Information on recent mergers, acquisitions, collaborations, agreements, partnerships, product launches, and expansions in the market and a relevant patent analysis
• Detailed company profiles of major players in the market of the industry, including AbbVie, Daiichi Sankyo, GlaxoSmithKline PLC, Pfizer Inc. and Servier

Table of Contents

Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Information Sources
Primary Research
Secondary Research
Geographic Breakdown
Chapter 2 Summary and Highlights
Market Outlook
This Report Highlights
Chapter 3 Market Overview and Definitions
Overview
Acute Myeloid Leukemia
The Global Regulatory Structure for AML
Pricing and Reimbursement for AML
Therapies/Drugs to Treat AML
FLT3 Inhibitors
IDH Inhibitors
Apoptosis Stimulants
DNA Methylation Inhibitors
DNA Intercalators
Angiogenesis Inhibitors
DNA Synthesis Inhibitors
Chapter 4 Market Dynamics
Market Drivers
Growing Elderly Population
Increasing Incidence and Prevalence
Advancements in Molecular Diagnostics
Minimal Residual Disease (MRD) Monitoring
Gene Expression Profiling
Fusion Gene Detection
Liquid Biopsies
R&D
Regulatory Environment
Personalized Medicine
Collaborative Efforts
Patient Advocacy and Awareness
Market Opportunity
Strategic Initiative
Market Restraints
High Costs
Limited Treatment Options
Treatment-related Toxicity and Adverse Effects
Regulatory and Reimbursement Challenges
Chapter 5 Impact of COVID-19
Introduction
COVID-19 Impact on AML Treatments
Chapter 6 Market Breakdown by Region
Market Overview and Discussion
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Market Breakdown by Treatment Type
Market Overview and Discussion
Targeted Therapy
Anthracycline Drugs
Other Chemotherapies
Targeted Therapy
Anthracycline Drugs
Other Chemotherapies
Chapter 8 Market Breakdown by Route of Administration
Market Overview and Discussion
Intravenous (IV) Administration
Oral Administration
Intravenous (IV) Administration
Chapter 9 Market Breakdown by Product
FLT3 Inhibitors
Apoptosis Stimulants
Angiogenesis Inhibitors
DNA Methylation Inhibitors
DNA Synthesis Inhibitors
DNA Intercalators
Chapter 10 ESG Development
Introduction
Environment
Governance
Chapter 11 Emerging Trends and Technologies
Introduction
Chapter 12 Competitive Landscape
Overview
Industry Scenario
Company Shares
Chapter 13 Patent Analysis
Patent Analysis by Manufacturer
Chapter 14 Pipeline Analysis
Clinical Trail Scenario
Chapter 15 M&A and Venture Funding Outlook
Introduction
Chapter 16 Company Profiles
ABBVIE
AMGEN INC.
ASTELLAS PHARMA INC.
BAYER AG
BIOGEN
BRISTOL MYERS SQUIBB
DAIICHI SANKYO CO. LTD.
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
MERCK & CO. INC.
NOVARTIS
PFIZER INC.
SANOFI
SERVIER LABORATORIES
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Chapter 17 Appendix: Acronyms

List of Tables
Summary Table : Global Market for AML Treatments, by Drug Type, Through 2028
Table 1 : Global Population, Aged 60+, 2010-2050
Table 2 : North America, New Patents, 2023
Table 3 : AML Treatment: Targeted Therapy Drugs
Table 4 : AML Treatment Cost, by Country
Table 5 : AML Treatment-related Toxicities and Adverse Effects
Table 6 : Global COVID-19 Cases, 2023
Table 7 : Global Market for AML Treatments, by Region, Through 2028
Table 8 : North American Market for AML Treatments, by Country, Through 2028
Table 9 : European Market for AML Treatments, by Country, Through 2028
Table 10 : Asia-Pacific Market for AML Treatments, by Country, Through 2028
Table 11 : RoW Market for AML Treatments, Through 2028
Table 12 : Global AML, by Treatment Type, Targeted Therapy
Table 13 : Global Market for AML Treatments, by Targeted Therapy, Through 2028
Table 14 : Global Market for AML Treatments, by Anthracycline Drugs, Through 2028
Table 15 : Global Market for AML Treatments, by Other Chemotherapies, Through 2028
Table 16 : Global Market for AML Treatments, by IV Administration, Through 2028
Table 17 : Global AML IV Treatment
Table 18 : Global AML IV Treatment Cycle
Table 19 : Global Market for AML Treatments, by Oral Route Administration, Through 2028
Table 20 : Global AML, Oral Treatment
Table 21 : Global Market for AML Treatments, by Product, Through 2028
Table 22 : Global Market for AML Treatments, FLT3 Inhibitors, Through 2028
Table 23 : Global Market for AML Treatments, Apoptosis Stimulants, Through 2028
Table 24 : Global Market for AML Treatments, IDH Inhibitors, Through 2028
Table 25 : Global Market for AML Treatments, Angiogenesis Inhibitors, Through 2028
Table 26 : Global Market for AML Treatments, DNA Methylation Inhibitors, Through 2028
Table 27 : Global Market for AML Treatments, DNA Synthesis Inhibitors, Through 2028
Table 28 : Global Market for AML Treatments, DNA Intercalators, Through 2028
Table 29 : ESG Framework for the Global Pharmaceutical Industry
Table 30 : Social Framework, Global Pharmaceutical Industry
Table 31 : Top Pharma Companies, ESG Ratings
Table 32 : Global Market for AML Treatments, New Technologies
Table 33 : Global AML Treatments, by Company Market Share, 2022
Table 34 : Global AML Treatments, by Product Share, 2022
Table 35 : Global AML Treatments, by Product Sales, 2022
Table 36 : Global AML Treatments, Company Information
Table 37 : Global AML Treatments, Key Financials, 2022
Table 38 : Patents on AML Drugs, 2018-Present
Table 39 : Selected Manufacturer Patents on AML Drugs, 2018-Present
Table 40 : Patents on FLT3 Inhibitors, 2018-Present
Table 41 : Selected Manufacturer Patents on FLT3 Inhibitors, 2018-Present
Table 42 : Patents on Apoptosis Stimulants, 2018-Present
Table 43 : Selected Manufacturer Patents on Apoptosis Stimulants, 2018-Present
Table 44 : Patents on IDH Inhibitors, 2018-Present
Table 45 : Selected Manufacturer Patents on IDH Inhibitors, 2018-Present
Table 46 : Patents on Anaplastic Lymphoma Kinase Inhibitors, 2018-Present
Table 47 : Selected Manufacturer Patents on Anaplastic Lymphoma Kinase Inhibitors, 2018-Present
Table 48 : Patents on DNA Methylation Inhibitor, 2018-Present
Table 49 : Selected Manufacturer Patents on DNA Methylation Inhibitor, 2018-Present
Table 50 : Selected Apoptosis Stimulants in Clinical Trials, 2023
Table 51 : Selected IDH Inhibitors in Clinical Trials, 2023
Table 52 : Selected IDH Inhibitors in Clinical Trials, 2023
Table 53 : Selected DNA Methylation Inhibitors in Clinical Trials, 2023.
Table 54 : Selected FLT3 Inhibitors in Clinical Trials, 2023
Table 55 : Selected DNA Synthesis Inhibitors in Clinical Trials, 2023
Table 56 : Global AML Treatment Market: Mergers and Acquisitions, 2019-2022
Table 57 : AbbVie: Product Information
Table 58 : AbbVie: Revenue, 2020-2022
Table 59 : AbbVie: Recent Key Developments
Table 60 : Amgen: Revenue, 2020-2022
Table 61 : Amgen: Key Developments, 2021 and 2022
Table 62 : Astellas Pharma: Revenue, 2020-2022
Table 63 : Astellas Pharma: Recent Key Developments
Table 64 : Bayer AG: Marketed Products
Table 65 : Bayer AG: Annual Revenue, 2020-2022
Table 66 : Bayer AG: Key Developments, 2022 and 2023
Table 67 : Biogen: Annual Revenue, 2020-2022
Table 68 : Biogen: Key Developments, 2018-2023
Table 69 : Bristol-Myers Squibb: Product Information
Table 70 : Bristol-Myers Squibb: Revenue, 2020-2022
Table 71 : Bristol-Myers Squibb: Key Developments, 2020 and 2021
Table 72 : Daiichi Sankyo: Product Information
Table 73 : Daiichi Sankyo: Annual Revenue, 2020-2022
Table 74 : Daiichi Sankyo: Key Developments, 2022 and 2023
Table 75 : Gilead Sciences: Annual Revenue, 2020-2022
Table 76 : Gilead Sciences: Key Developments, 2022 and 2023
Table 77 : GlaxoSmithKline PLC: Product Segment
Table 78 : GlaxoSmithKline PLC: Annual Revenue, 2020-2022
Table 79 : GlaxoSmithKline PLC: Recent Developments, 2022
Table 80 : Merck & Co. Inc.: Business Segment
Table 81 : Merck & Co. Inc.: Annual Revenue, 2020-2022
Table 82 : Merck & Co. Inc.: Key Developments, 2022
Table 83 : Novartis: Product Information
Table 84 : Novartis: Revenue, 2020-2022
Table 85 : Novartis: Key Developments
Table 86 : Pfizer Inc.: Product Segments
Table 87 : Pfizer Inc.: Annual Revenue, 2020-2022
Table 88 : Pfizer Inc.: Top Brands, 2022
Table 89 : Pfizer Inc.: Key Developments, 2019-2023
Table 90 : Sanofi: Business Segment
Table 91 : Sanofi: Annual Revenue, 2020-2022
Table 92 : Sanofi: Key Developments, 2021-2023
Table 93 : Servier: Product Information
Table 94 : Servier: Annual Revenue, 2020-2022
Table 95 : Servier: Key Developments, 2022 and 2023
Table 96 : Teva: Financials, 2020-2022
Table 97 : Teva: Key Developments, 2021-2023
Table 98 : Acronyms Used in This Report

List of Figures
Summary Figure A : Global Market for AML Treatments, by Drug Type, 2020-2028
Summary Figure B : Global Market Shares of AML Treatments, by Drug Type, 2022
Figure 1 : Global Market Shares of AML Treatments, by Region, 2022
Figure 2 : North American Market Shares of AML Treatments, by Country, 2022
Figure 3 : European Market Shares of AML Treatments, by Country, 2022
Figure 4 : Asia-Pacific Market Shares of AML Treatments, by Country, 2022
Figure 5 : Global AML Treatment Market Shares, by Drug Type, 2022
Figure 6 : Global Market Shares of AML Treatments, by Route of Administration, 2022
Figure 7 : Global Market Shares of AML Treatments, by Oral Route Administration, 2022
Figure 8 : Global Market Shares of AML Treatments, by Product, Through 2028
Figure 9 : Global Electricity from Renewable Sources, 2017-2021
Figure 10 : Global Recycled Waste, 2017-2021
Figure 11 : Global CO₂ Emissions, 2017-2021
Figure 12 : Global AML Treatments, by Company Market Share, 2022
Figure 13 : Global AML Treatments, by Product Sales, 2022
Figure 14 : AbbVie: Market Share, by Country, 2022
Figure 15 : Bristol-Myers Squibb: Revenue Share, by Country, 2022
Figure 16 : Daiichi Sankyo: Market Share, by Region/Country, 2022
Figure 17 : Gilead Sciences: Revenue, by Product, 2022
Figure 18 : GlaxoSmithKline PLC: Annual Revenue, by Segment, 2020-2022
Figure 19 : Merck & Co. Inc.: Annual Revenue, by Segment, 2020-2022
Figure 20 : Novartis Innovative Medicine: Market Share, by Region/Country, 2022
Figure 21 : Novartis Sandoz: Market Share, by Region/Country, 2022
Figure 22 : Sanofi: Revenue, by Region/Country, 2022
Figure 23 : Sanofi: Revenue, by Segment, 2022
Figure 24 : Teva: Market Share, by Region, 2022